These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29277754)

  • 1. Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
    Damaskos C; Tomos I; Garmpis N; Karakatsani A; Dimitroulis D; Garmpi A; Spartalis E; Kampolis CF; Tsagkari E; Loukeri AA; Margonis GA; Spartalis M; Andreatos N; Schizas D; Kokkineli S; Antoniou EA; Nonni A; Tsourouflis G; Markatos K; Kontzoglou K; Kostakis A; Tomos P
    Anticancer Res; 2018 Jan; 38(1):37-43. PubMed ID: 29277754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
    Ruiz R; Raez LE; Rolfo C
    Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors in non-small-cell lung cancer.
    Witta S
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S404-6. PubMed ID: 23160335
    [No Abstract]   [Full Text] [Related]  

  • 4. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
    Petta V; Gkiozos I; Strimpakos A; Syrigos K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
    Neal JW; Sequist LV
    J Clin Oncol; 2012 Jun; 30(18):2280-2. PubMed ID: 22508823
    [No Abstract]   [Full Text] [Related]  

  • 6. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2008 Oct; 68(1):29-36. PubMed ID: 18424067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
    Vendetti FP; Rudin CM
    Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
    Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
    Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
    Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer.
    Zhu L; Wu K; Ma S; Zhang S
    Tumori; 2015; 101(3):257-62. PubMed ID: 25953446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
    Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
    Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G; Gekeler V; Leja A; Beckers T; Boehm M
    Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
    Gryder BE; Sodji QH; Oyelere AK
    Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
    Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
    Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
    Markozashvili D; Ribrag V; Vassetzky YS
    Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of histone deacetylase as antitumor agents: A critical review.
    Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
    Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.